Phase 1 Evaluation of MK-1084 in Patients with KRAS Mutant Advanced Solid Tumors, Including Lung Cancer

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **MK-1084** in patients with **KRAS mutant advanced solid tumors**, including **lung cancer**. This is clinically relevant as KRAS mutations are common in various cancers and are associated with poor prognosis and resistance to certain therapies. Understanding the safety profile of MK-1084 could provide insights into its potential as a therapeutic option for these challenging cases.

The clinical trial involves a total of **769 participants** diagnosed with **solid tumor cancer** and **lung cancer**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial does not specify any particular lifestyle factors that may influence the study outcomes.

The clinical trial is a **Phase 1** study designed to evaluate the investigational treatment in patients with **solid tumor cancer** and **lung cancer**. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from December 16, 2021, to September 15, 2026, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough review of the participant's medical history and current health status. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the safety and efficacy of the treatment, as well as to collect necessary data for the study endpoints. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement in the trial is determined by the study protocol, with specific timelines for each phase of the trial. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study procedures, or withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date was December 16, 2021, with an anticipated end date of September 15, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials typically involve initial assessments of therapeutic effects alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, to ensure the reliability and accuracy of the efficacy assessments. The analysis of these parameters will be conducted at predetermined timepoints throughout the trial duration to monitor progress and determine the potential therapeutic benefits of the investigational product.